Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal replacement therapy for acute renal failure (VERROU-REA study): study protocol for a randomized controlled trial

Rémi Bruyère, Agnès Soudry-Faure, Gilles Capellier, Christine Binquet, Abdelouaid Nadji, Stephane Torner, Gilles Blasco, Maria Yannaraki, Saber Davide Barbar, Jean-Pierre Quenot, Rémi Bruyère, Agnès Soudry-Faure, Gilles Capellier, Christine Binquet, Abdelouaid Nadji, Stephane Torner, Gilles Blasco, Maria Yannaraki, Saber Davide Barbar, Jean-Pierre Quenot

Abstract

Background: The incidence of acute kidney injury (AKI) is estimated at 10 to 20% in patients admitted to intensive care units (ICU) and often requires renal replacement therapy (RRT). ICU mortality in AKI patients can exceed 50%. Venous catheters are the preferred vascular access method for AKI patients requiring RRT, but carry a risk of catheter thrombosis or infection. Catheter lock solutions are commonly used to prevent such complications. Heparin and citrate locks are both widely used for tunneled, long-term catheters, but few studies have compared citrate versus heparin for patients with short-term, non-tunneled catheters. We aim to compare citrate 4% catheter lock solution versus heparin in terms of event-free survival of the first non-tunneled hemodialysis catheter inserted in ICU patients with AKI requiring RRT. Secondary objectives are the rate of fibrinolysis, incidence of catheter thrombosis and catheter-related infection per 1,000 catheter days, length of stay in ICU and in-hospital and 28-day mortality.

Methods/design: The VERROU-REA study is a randomized, prospective, multicenter, double-blind, parallel-group, controlled superiority study carried out in the medical, surgical and nephrological ICUs of two large university hospitals in eastern France. A catheter lock solution composed of trisodium citrate at 4% will be compared to unfractionated heparin at a concentration of 5,000 IU/mL. All consecutive adult patients with AKI requiring extracorporeal RRT, and in whom a first non-tunneled catheter is to be inserted by the jugular or femoral approach, will be eligible. Catheters inserted by the subclavian approach, patients with acute liver failure, thrombopenia or contraindication to systemic anticoagulation will be excluded. Patients will be followed up daily in accordance with standard practices for RRT until death or discharge.

Discussion: Data is scarce regarding the use of non-tunneled catheters in the ICU setting in patients with AKI. This study will provide an evidence base for recommendations regarding the use of anticoagulant catheter locks for the prevention of dysfunction in non-tunneled hemodialysis catheters in patients with AKI in critical or intensive care.

Trial registration: Registered with Clinicaltrials.gov (registration number: NCT01962116) on 27 August 2013.

References

    1. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet. 2005;365:417–430. doi: 10.1016/S0140-6736(05)17831-3.
    1. Tillyard A, Keays R, Soni N. The diagnosis of acute renal failure in intensive care: mongrel or pedigree? Anaesthesia. 2005;60:903–914. doi: 10.1111/j.1365-2044.2005.04278.x.
    1. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C, Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294:813–818. doi: 10.1001/jama.294.7.813.
    1. Sutton TA, Fisher CJ, Molitoris BA. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int. 2002;62:1539–1549. doi: 10.1046/j.1523-1755.2002.00631.x.
    1. Bagshaw SM, George C, Bellomo R. Changes in the incidence and outcome for early acute kidney injury in a cohort of Australian intensive care units. Crit Care. 2007;11:R68. doi: 10.1186/cc5949.
    1. Cruz DN, Ronco C. Acute kidney injury in the intensive care unit: current trends in incidence and outcome. Crit Care. 2007;11:149. doi: 10.1186/cc5965.
    1. Hoste EA, Schurgers M. Epidemiology of acute kidney injury: how big is the problem? Crit Care Med. 2008;36:S146–S151. doi: 10.1097/CCM.0b013e318168c590.
    1. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34:344–353. doi: 10.1097/01.CCM.0000194725.48928.3A.
    1. Agee KR, Balk RA. Central venous catheterization in the critically ill patient. Crit Care Clin. 1992;8:677–686.
    1. Canaud B, Leray-Moragues H, Leblanc M, Klouche K, Vela C, Beraud JJ. Temporary vascular access for extracorporeal renal replacement therapies in acute renal failure patients. Kidney Int Suppl. 1998;66:S142–S150.
    1. Eggimann P, Harbarth S, Constantin MN, Touveneau S, Chevrolet JC, Pittet D. Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care. Lancet. 2000;355:1864–1868. doi: 10.1016/S0140-6736(00)02291-1.
    1. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol. 1996;7:523–535.
    1. McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med. 2003;348:1123–1133. doi: 10.1056/NEJMra011883.
    1. Karaaslan H, Peyronnet P, Benevent D, Lagarde C, Rince M, Leroux-Robert C. Risk of heparin lock-related bleeding when using indwelling venous catheter in haemodialysis. Nephrol Dial Transplant. 2001;16:2072–2074. doi: 10.1093/ndt/16.10.2072.
    1. Weijmer MC, van den Dorpel MA, Van de Ven PJ, ter Wee PM, van Geelen JA, Groeneveld JO, van Jaarsveld BC, Koopmans MG, le Poole CY, der Meer AM S-V, Siegert CE, Stas KJ, CITRATE Study Group Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol. 2005;16:2769–2777. doi: 10.1681/ASN.2004100870.
    1. Yevzlin AS, Sanchez RJ, Hiatt JG, Washington MH, Wakeen M, Hofmann RM, Becker YT. Concentrated heparin lock is associated with major bleeding complications after tunneled hemodialysis catheter placement. Semin Dial. 2007;20:351–354. doi: 10.1111/j.1525-139X.2007.00294.x.
    1. Murray PT, Hursting MJ. Heparin-induced thrombocytopenia in patients administered heparin solely for hemodialysis. Ren Fail. 2006;28:537–539. doi: 10.1080/08860220600843813.
    1. Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med. 2007;35:1165–1176. doi: 10.1097/01.CCM.0000259538.02375.A5.
    1. Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T. Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis. 1996;28:82–85. doi: 10.1016/S0272-6386(96)90134-1.
    1. Bauer E, Derfler K, Joukhadar C, Druml W. Citrate kinetics in patients receiving long-term hemodialysis therapy. Am J Kidney Dis. 2005;46:903–907. doi: 10.1053/j.ajkd.2005.07.041.
    1. Follea G, Laville M, Pozet N, Dechavanne M. Pharmacokinetic studies of standard heparin and low molecular weight heparin in patients with chronic renal failure. Haemostasis. 1986;16:147–151.
    1. Ashouri OS. Regional sodium citrate anticoagulation in patients with active bleeding undergoing hemodialysis. Uremia Invest. 1985;9:45–51.
    1. Ashton DN, Mehta RL, Ward DM, McDonald BR, Aguilar MM. Recent advances in continuous renal replacement therapy: citrate anticoagulated continuous arteriovenous hemodialysis. ANNA J. 1991;18:263–267.
    1. Bach A, Bohrer H, Motsch J, Martin E, Geiss HK, Sonntag HG. Prevention of catheter-related infections by antiseptic bonding. J Surg Res. 1993;55:640–646. doi: 10.1006/jsre.1993.1197.
    1. Ash SR, Mankus RA, Sutton JM, Criswell RE, Crull CC, Velasquez KA, Smeltzer BD, Ing TS. Concentrated sodium citrate (23%) for catheter lock. Hemodial Int. 2000;4:22–31.
    1. Raad I, Buzaid A, Rhyne J, Hachem R, Darouiche R, Safar H, Albitar M, Sherertz RJ. Minocycline and ethylenediaminetetraacetate for the prevention of recurrent vascular catheter infections. Clin Infect Dis. 1997;25:149–151. doi: 10.1086/514518.
    1. Stas KJ, Vanwalleghem J, De Moor B, Keuleers H. Trisodium citrate 30% vs. heparin 5% as catheter lock in the interdialytic period in twin- or double-lumen dialysis catheters for intermittent haemodialysis. Nephrol Dial Transplant. 2001;16:1521–1522. doi: 10.1093/ndt/16.7.1521-a.
    1. Weijmer MC, Debets-Ossenkopp YJ, Van De Vondervoort FJ, ter Wee PM. Superior antimicrobial activity of trisodium citrate over heparin for catheter locking. Nephrol Dial Transplant. 2002;17:2189–2195. doi: 10.1093/ndt/17.12.2189.
    1. Moran JE, Ash SR. Locking solutions for hemodialysis catheters; heparin and citrate–a position paper by ASDIN. Semin Dial. 2008;21:490–492. doi: 10.1111/j.1525-139X.2008.00466.x.
    1. Vanholder R, Canaud B, Fluck R, Jadoul M, Labriola L, Marti-Monros A, Tordoir J, Van Biesen W. Catheter-Related Blood Stream Infections (CRBSI): a European view. Nephrol Dial Transplant. 2010;25:1753–1756. doi: 10.1093/ndt/gfq205.
    1. Cardinal P, Allan J, Pham B, Hindmarsh T, Jones G, Delisle S. The effect of sodium citrate in arterial catheters on acid–base and electrolyte measurements. Crit Care Med. 2000;28:1388–1392. doi: 10.1097/00003246-200005000-00021.
    1. Flanigan MJ, Von Brecht J, Freeman RM, Lim VS. Reducing the hemorrhagic complications of hemodialysis: a controlled comparison of low-dose heparin and citrate anticoagulation. Am J Kidney Dis. 1987;9:147–153. doi: 10.1016/S0272-6386(87)80092-6.
    1. Polaschegg HD, Sodemann K. Risks related to catheter locking solutions containing concentrated citrate. Nephrol Dial Transplant. 2003;18:2688–2690. doi: 10.1093/ndt/gfg481.
    1. Dogra GK, Herson H, Hutchison B, Irish AB, Heath CH, Golledge C, Luxton G, Moody H. Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: a randomized controlled study. J Am Soc Nephrol. 2002;13:2133–2139. doi: 10.1097/01.ASN.0000022890.29656.22.
    1. Grudzinski L, Quinan P, Kwok S, Pierratos A. Sodium citrate 4% locking solution for central venous dialysis catheters–an effective, more cost-efficient alternative to heparin. Nephrol Dial Transplant. 2007;22:471–476. doi: 10.1093/ndt/gfl606.
    1. Lok CE, Appleton D, Bhola C, Khoo B, Richardson RM. Trisodium citrate 4% – an alternative to heparin capping of haemodialysis catheters. Nephrol Dial Transplant. 2007;22:477–483. doi: 10.1093/ndt/gfl570.
    1. Macrae JM, Dojcinovic I, Djurdjev O, Jung B, Shalansky S, Levin A, Kiaii M. Citrate 4% versus Heparin and the Reduction of Thrombosis Study (CHARTS) Clin J Am Soc Nephrol. 2008;3:369–374. doi: 10.2215/CJN.01760407.
    1. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957–2963. doi: 10.1001/jama.1993.03510240069035.
    1. Twardowski ZJ. The clotted central vein catheter for haemodialysis. Nephrol Dial Transplant. 1998;13:2203–2206. doi: 10.1093/ndt/13.9.2203.
    1. Twardowski ZJ. High-dose intradialytic urokinase to restore the patency of permanent central vein hemodialysis catheters. Am J Kidney Dis. 1998;31:841–847. doi: 10.1016/S0272-6386(98)70054-X.
    1. Hermite L, Quenot JP, Nadji A, Barbar SD, Charles PE, Hamet M, Jacquiot N, Ghiringhelli F, Freysz M. Sodium citrate versus saline catheter locks for non-tunneled hemodialysis central venous catheters in critically ill adults: a randomized controlled trial. Intensive Care Med. 2012;38:279–285. doi: 10.1007/s00134-011-2422-y.
    1. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976;34:585–612. doi: 10.1038/bjc.1976.220.
    1. Oliver MJ. Acute dialysis catheters. Semin Dial. 2001;14:432–435. doi: 10.1046/j.1525-139x.2001.00107.x.
    1. Hryszko T, Brzosko S, Mazerska M, Malyszko J, Mysliwiec M. Risk factors of nontunneled noncuffed hemodialysis catheter malfunction. A prospective study. Nephron Clin Pract. 2004;96:c43–c47. doi: 10.1159/000076398.
    1. Mrozek N, Lautrette A, Timsit JF, Souweine B. How to deal with dialysis catheters in the ICU setting. Ann Intensive Care. 2012;2:48. doi: 10.1186/2110-5820-2-48.
    1. Hannah EL, Stevenson KB, Lowder CA, Adcox MJ, Davidson RL, Mallea MC, Narasimhan N, Wagnild JP. Outbreak of hemodialysis vascular access site infections related to malfunctioning permanent tunneled catheters: making the case for active infection surveillance. Infect Control Hosp Epidemiol. 2002;23:538–541. doi: 10.1086/502103.
    1. Marr KA, Sexton DJ, Conlon PJ, Corey GR, Schwab SJ, Kirkland KB. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med. 1997;127:275–280. doi: 10.7326/0003-4819-127-4-199708150-00003.
    1. Suhocki PV, Conlon PJ, Jr, Knelson MH, Harland R, Schwab SJ. Silastic cuffed catheters for hemodialysis vascular access: thrombolytic and mechanical correction of malfunction. Am J Kidney Dis. 1996;28:379–386. doi: 10.1016/S0272-6386(96)90495-3.
    1. Parienti JJ, Mégarbane B, Fischer MO, Lautrette A, Gazui N, Marin N, Hanouz JL, Ramakers M, Daubin C, Mira JP, Charbonneau P, du Cheyron D, Cathedia Study Group Catheter dysfunction and dialysis performance according to vascular access among 736 critically ill adults requiring renal replacement therapy: a randomized controlled study. Crit Care Med. 2010;38:1118–1125. doi: 10.1097/CCM.0b013e3181d454b3.
    1. Dittmer ID, Sharp D, McNulty CA, Williams AJ, Banks RA. A prospective study of central venous hemodialysis catheter colonization and peripheral bacteremia. Clin Nephrol. 1999;51:34–39.
    1. Moist LM, Trpeski L, Na Y, Lok CE. Increased hemodialysis catheter use in Canada and associated mortality risk: data from the Canadian organ replacement registry 2001–2004. Clin J Am Soc Nephrol. 2008;3:1726–1732. doi: 10.2215/CJN.01240308.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir